Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kiran Mian

Dermatology New York, NY Doctor of Osteopathy

NPI 1942681200 CMS profile 1390175

12 W 21St St Fl 6, New York, NY 10010

Open in the dashboard

General payments

$103,140

193 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kiran Mian of New York, NY is reported in the CMS Open Payments database as having received $103,140 across 193 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $64,962 54
2024 General $34,601 46
2023 General $586 23
2022 General $768 8
2021 General $1,018 26
2020 General $468 16
2019 General $737 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kiran Mian
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Kiran Mian were reported at $64,962. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Kiran Mian Dermatology median Middle half National median
2019 $737 $454 $129–$1,240 $163
2020 $468 $235 $81–$756 $114
2021 $1,018 $377 $108–$1,108 $132
2022 $768 $514 $143–$1,391 $149
2023 $586 $607 $159–$1,674 $160
2024 $34,601 $751 $204–$1,903 $164
2025 $64,962 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Galderma Laboratories, L.P. $94,480 29 payments
  2. AbbVie, Inc. $4,237 35 payments
  3. Allergan Inc. $1,552 20 payments
  4. Lilly USA, LLC $582 21 payments
  5. Janssen Biotech, Inc. $573 21 payments
  6. Regeneron Healthcare Solutions, Inc. $307 13 payments
  7. Novartis Pharmaceuticals Corporation $196 5 payments
  8. LEO Pharma Inc. $186 8 payments
  9. Pfizer Inc. $184 9 payments
  10. Genzyme Corporation $142 2 payments
  11. Other $701 30 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $89,693 6 payments
  2. Consulting Fee $6,613 4 payments
  3. Food and Beverage $5,209 173 payments
  4. Travel and Lodging $1,460 8 payments
  5. Education $165 2 payments
Products named General payments · program years 2019–2025
  1. BOTOX $857 18 payments
  2. TREMFYA $525 19 payments
  3. BOTOX COSMETIC $476 12 payments
  4. TALTZ $407 18 payments
  5. DUPIXENT Inflammation And Immunology $218 9 payments
  6. ADBRY $186 8 payments
  7. EUCRISA $184 9 payments
  8. OLUMIANT $153 2 payments
  9. EBGLYSS $150 6 payments
  10. DUPIXENT Immunology $142 2 payments
  11. Other $1,662 68 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

193 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record